自拟宝肾方治疗慢性肾脏病2～3期患者的临床疗效观察

Clinical effects of Baoshenfang on patients with chronic kidney disease at 2-3 stage

目的：观察自拟宝肾方对慢性肾脏病（CKD ）2～3期患者的临床疗效及安全性。方法将65例明确诊断为CKD 2～3期患者随机分为治疗组（n＝34例）和对照组（n＝31例）。对照组给予西医常规基础治疗；治疗组在对照组基础上加用自拟宝肾方治疗。分别于6个月及12个月后观察两组疗效。检测血胱抑素C（Cys-c）、血肌酐（SCr）、肾小球滤过率（eGFR）、24 h尿蛋白定量（24 h-UTP）以及胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白（HDL）、低密度脂蛋白（VDL）。结果①治疗6个月后，宝肾方组Cys-C水平明显降低（P＜0．05）；但与对照组比较，降低不明显（P＞0．05）。治疗12个月后，宝肾方组 Cys-C明显降低（P＜0.05）；与对照组比较，亦有明显降低（P＜0.05）。②宝肾方组治疗6个月后，Scr、eGFR水平均无明显变化（P＞0．05）；与对照组比较，变化不明显（P＞0．05）。治疗12个月后，宝肾方组Scr有降低趋势，eGFR有升高趋势，变化不明显（P＞0．05）；但与对照组比较，有明显变化（P＜0．05）。③治疗6个月后，宝肾方组24 h-UTP水平明显降低（P＜0．05）；但与对照组比较，降低不明显（P＞0．05）。治疗12个月后，宝肾方组24 h-UTP较治疗前明显降低（P＜0．05）；与对照组比较，亦有明显降低（P＜0．05）。④治疗6个月后，宝肾方组TC、TG、HDL以及VDL水平均无明显变化（P＞0．05）；与对照组比较，变化均不明显（P＞0．05）。治疗12个月后，宝肾方组血脂四项有明显变化（P＜0．05）；与对照组比较，亦有明显变化（P＜0．05）。结论宝肾方可改善CKD 2～3期患者的肾功能，降低尿蛋白，调节脂代谢，具有一定的肾脏保护和延缓CKD进展的作用。

Objective To observe the clinical effects of Baoshenfang in the treatment of patients with chronic kidney disease at 2-3 stage .Methods Totally 65 cases with chronic kidney disease at 2-3 stage were randomly as-signed to two groups .The control group （31 cases） treated with routine therapy ;the treatment group （34 cases） treated with routine therapy ,and added Baoshenfang for 12 months .The data of Cys-c ,Scr ,eGFR ,24 h-UTP ,TC , TG ,HDL and VDL were detected respectively in 0 ,6 and 12 month .Results ① After 6 months treatment ,the levels of Cys-c statistically decreased in the treatment group （P〈0 .05） ,but no statistical significance in difference between the treatment group and the control group （P〉0 .05） .After 12 months treatment ,the Cys-c statistically decreased in the treatment group （P〈0 .05） ,and there was statistical significance in difference between the treat-ment group and the control group （P〈 0 .05） ② After 6 months treatment ,the levels of Scr and eGFR were no change in the treatment group （P〉0 .05） .After 12 months treatment ,the levels of Scr decreased and eGFR in-creased in the treatment group ,and there was statistical significance in difference between the treatment group and the control group （P〈0 .05） ③After 6 months treatment ,the levels of 24 h-UTP statistically decreased in the treat-ment group （P〈 0 .05） ,but no statistical significance in difference between the treatment group and the control group （P〉 0.05） .After 12 months treatment ,the 24 h-UTP statistically decreased in the treatment group （P〈0.05） ,and there was statistical significance in difference between the treatment group and the control group （ P〈0.05） .④After 6 months treatment ,the levels of TC ,TG ,HDL and VDL were no change in the treatment group （P〉0 .05） .After 12 months treatment ,the TC ,TG ,HDL and VDL statistically changed in the treatment group （P〈0 .05） ,and there was statistical significance in difference between the treatment group and the control group （P〈0 . 05） .Conclusion Baoshenfang could be used to improve the renal function and relieve the proteinuria and adjust the blood lipid levels of patients with chronic kidney disease at 2-3 stage ,thus delaying the progress of chronic kid-ney disease .